In neuroprotection trials for neonatal encephalopathy, the typical clinical outcome measures can only be measured reliably after a period of years. In a multicentre study covering eight sites and recruiting 224 infants, we demonstrate that MRS measures made within two weeks of birth provide quantitative and objective tools for predicting neurodevelopmental abnormalities usually only observed years after the initial injury. In particular, the thalamic concentration of tNAA (N-acetyl aspartate + N-acetyl aspartyl glutamate) has an area under the receiver operating characteristic curve of 0.99 (95%CI 0.98–1.00, n=82). Such tools could greatly speed up the next generation of clinical trials.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords